It isn't settled yet in my opinion. Except safety profile, Tricor's number for reduction of triglyceride and LDL-C looked much more impressive. However, outcome trials didn't come out favorable. The main risk with AMRN reaching its potential valuation is the outcome trial. FDA requires the trial to be substantially underway before approval in 200-500mg/dl TG population. So outcome trial result will be out just a few short years after AMR101 coming to market. I don't think ABT would want to have two drugs for same purpose, but two negative outcome trials in hand.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.